Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aquestive Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AQST
Nasdaq
2834
https://aquestive.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aquestive Therapeutics Inc
Aquestive Therapeutics Announces CEO Transition
- May 17th, 2022 8:01 pm
When Will Aquestive Therapeutics, Inc. (NASDAQ:AQST) Become Profitable?
- May 14th, 2022 12:27 pm
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
- May 10th, 2022 12:00 pm
Aquestive Therapeutics, Inc. (AQST) Q1 2022 Earnings Call Transcript
- May 4th, 2022 6:30 pm
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
- May 3rd, 2022 10:55 pm
Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
- May 3rd, 2022 9:41 pm
Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET
- Apr 18th, 2022 12:00 pm
Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital
- Apr 13th, 2022 12:00 pm
Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
- Apr 12th, 2022 12:00 pm
Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions
- Mar 17th, 2022 3:17 pm
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
- Mar 17th, 2022 12:00 pm
Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Call Transcript
- Mar 9th, 2022 10:30 pm
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
- Mar 8th, 2022 11:15 pm
Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance
- Mar 8th, 2022 9:56 pm
Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China
- Mar 3rd, 2022 1:00 pm
What Is The Ownership Structure Like For Aquestive Therapeutics, Inc. (NASDAQ:AQST)?
- Mar 2nd, 2022 9:53 am
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
- Mar 1st, 2022 10:45 pm
Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
- Mar 1st, 2022 1:33 am
Aquestive Highlights Early Data From Allergy Treatment Candidate AQST-109 Study
- Feb 25th, 2022 3:48 pm
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
- Feb 25th, 2022 12:45 pm
Scroll